MY104530A - Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. - Google Patents

Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.

Info

Publication number
MY104530A
MY104530A MYPI90002043A MYPI19902043A MY104530A MY 104530 A MY104530 A MY 104530A MY PI90002043 A MYPI90002043 A MY PI90002043A MY PI19902043 A MYPI19902043 A MY PI19902043A MY 104530 A MY104530 A MY 104530A
Authority
MY
Malaysia
Prior art keywords
hiv
recombinant
particles
nonreplicating
immunogens
Prior art date
Application number
MYPI90002043A
Inventor
W Senear Allen
M Travis Bruce
Hu Shiu-Lok
K Haffar Omar
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of MY104530A publication Critical patent/MY104530A/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

NONREPLICATING RECOMBINANT- MADE RETROVIRAL PARTICLES HAVING STRUCTURAL, MORPHOLOGICAL AND IMMUNOLOGICAL CHARACTERICTICS VERY SIMILAR TO THOSE OF NATIVE HUMAN RETROVIRUSES ARE DESCRIBED. THE METHOD OF THE INVENTION INVOLVES COEXPRESSION OF MATURE RETROVIRAL CORE AND ENVOLOPE STRUCTURAL PROTEINS IN MAMMALIAN HOST CELLS SUCH THAT THE EXPRESSED RETROOVIRAL PROTEINS ASSOCIATE INTO ASSEMBLED BUDDING RETROVIRAL PARTICLES. IN A PARTICULAR EMBODIMENT OF THE INVENTION NONREPLICATING RECOMBINANT- MADE HIV- 1 PARTICLES ARE PRODUCED BY COINFACTING MAMMALIAN HOST CELLS WITH A RECOMBINANT VACCINIA VIRUS CARRYING THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV- 1) GAG AND PROTEASE GENES AND A RECOMBINANT VACCINIA VIRUS CARRYING THE HIV- 1 ENV GENE. THESE NONREPLICATING RECOMBINANT- MADE HIV- 1PARTICLES HAVE IMMUNOLOGICAL AND MORPHOLOGICAL CHARACTERISTICS CLOSELY RESEMBLING THOSE OF NATIVE HIV- 1, ARE ABLE TO BLOCK THE INFECTIVITY OF LIVE HIV IN VITRO, AND ARE HIGHLY IMMUNOGENIC IN VIVO. THE RECOMBINANT- MADE HIV- 1 PARTICLES OF THE INVENTION MAY BE USED AS ANTI- VIRAL AGENTS AND AS IMMUNOGENS IN VACCINE FORMULATIONS EFFECTIVE AT INHIBITING OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME.
MYPI90002043A 1989-11-20 1990-11-20 Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. MY104530A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43920589A 1989-11-20 1989-11-20
US61575690A 1990-11-19 1990-11-19

Publications (1)

Publication Number Publication Date
MY104530A true MY104530A (en) 1994-04-30

Family

ID=27031958

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90002043A MY104530A (en) 1989-11-20 1990-11-20 Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.

Country Status (5)

Country Link
CN (1) CN1054613A (en)
IE (1) IE904161A1 (en)
IL (1) IL96404A0 (en)
MY (1) MY104530A (en)
PT (1) PT95939A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
EP1002091B1 (en) * 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1456382B1 (en) 2001-03-22 2007-08-08 The United States of America, represented by the Secretary, Department of Health and Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
CN104450631A (en) * 2014-11-11 2015-03-25 中国人民解放军第四军医大学 Enterovirus EV71 type VP1 gene virus-like particle as well as preparation method and application thereof

Also Published As

Publication number Publication date
CN1054613A (en) 1991-09-18
IE904161A1 (en) 1991-05-22
IL96404A0 (en) 1991-08-16
PT95939A (en) 1991-09-13

Similar Documents

Publication Publication Date Title
NO921969L (en) NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS
Karacostas et al. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.
Hahn et al. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.
Binley et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
DK33190A (en) HIV-3 RETROVIRUS AND ITS USE
Göttlinger et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.
Morikawa et al. Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus
DK0495811T3 (en) Production of genetically engineered vaccines against AIDS and other retroviral diseases
EP0265785A3 (en) Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells
WO1990015066A3 (en) Nucleotidic sequences resulting from the retrovirus gemone of the hiv-1, hiv-2, and siv type, and their applications, in particular for the amplification of the genomes of said retroviruses and for the in vitro diagnosis of infections caused by these viruses
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
ES2140380T3 (en) DNA SEQUENCES THAT CODE MODIFIED RETROVIRIC POLYPEPTIDES AND VACCINES THAT CONTAIN THEM OR ADDED THEREOF.
JP2004509601A5 (en)
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
YOURNO et al. Nucleotide sequence analysis of the env gene of a new Zairian isolate of HIV-1
Matthews et al. Prospects for development of a vaccine against HTLV-III-related disorders
SHAROVA et al. p17 and p17-containing gag precursors of input human immunodeficiency virus are transported into the nuclei of infected cells
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
RU2006123079A (en) VIRUS PARTICLES CONTAINING A VECTOR ORIGINING FROM ALPHAVIRUS AND METHOD FOR PRODUCING THE SPECIFIED VIRUS PARTICLE
CA2339850A1 (en) A non-cytolytic recombinant hiv-1 vaccine
RANJBAR et al. Molecular characterization of an HIV type 1 isolate from Burundi
Ferdinand et al. Perspectives of HIV vaccine developments
WO2022035860A3 (en) Replication-competent adenovirus type 4-hiv env vaccines and their use